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Abstract 
Objective: We have demonstrated that pitavastatin, 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitor, enhanced human serum paraoxonase (PON1) 
gene promoter activity and that protein kinase C (PKC) activated PON1 
expression through Sp1, in cultured HepG2 cells. We investigated whether PKC 
was involved in pitavastatin-induced PON1 expression. Methods: PON1 gene 
promoter activity was assessed by a reporter gene assay using cultured Huh7 
cells. PON1 protein expression and PKC activation were measured by Western 
blotting. The binding activity of Sp1 to the PON1 gene upstream was analyzed 
by electrophoretic mobility shift assay (EMSA). Results: Both PON1 gene 
promoter activity and PON1 protein expression were elevated by pitavastatin 
stimulation. The effects of pitavastatin on PON1 promoter activity and PON1 
protein expression were attenuated by both bisindolylmaleimide IX 
(Ro-31-8220) and bisindolylmaleimide I. EMSA showed that pitavastatin 
increased the Sp1-PON1 DNA binding and this effect was attenuated by 
Ro-31-8220. Pitavastatin activated atypical PKC, but never conventional or 
  
novel PKC. Myristoylated pseudosubstrate peptide inhibitor of PKCζ abolished 
the pitavastatin-increased PON1 promoter activity, however calphostin C and 
Gö6976 (PKC inhibitors except for PKCζ) did not influence on the promoter 
activity. Additionally an overexpression of dominant negative form of PKCζ 
expression vector obviously decreased pitavastatin-induced PON1 promoter 
activation. Conclusions: These observations suggest that pitavastatin activates 
PKC, especially PKCζ isoform, which increases the binding intensity of Sp1 to 
PON1 DNA promoter responsible for enhanced the transcription of PON1 gene 
and increased PON1 protein expression in Huh7 cells.  
  
Introduction 
 Human serum paraoxonase (PON1) is an esterase, and associated with 
apolipoprotein A-I and J in high-density lipoprotein (HDL) [1, 2]. Previous data 
suggest that PON1 is a primary determinant of the antioxidant of HDL [3-5]. In 
PON1 knockout mice [6], atherosclerotic lesion formation was increased by 
feeding on a high fat and high cholesterol diet, meanwhile in PON1 transgenic 
mice [7], it was decreased. Mackness B et al reported that low paraoxonase 
activity is an independent risk factor for coronary events in male population [8]. 
In addition, we recent reported that PON1 concentration was related to 
cardiovascular mortality in patients on chronic hemodialysis [9]. These 
accumulating reports demonstrate that PON1 has effects against oxidative 
disorders and it plays an important role in the suppression of the development 
and progression of atherosclerosis.   
 The 3-hydroxyl-3-methylglutaryl co-enzyme A (HMG-CoA) reductase 
inhibitors (statins) are widely prescribed to lower cholesterol levels in patients at 
risk of cardiovascular diseases. Recent studies show that statins have many 
  
additional cardiovascular protective effects beyond the ability to lower serum 
cholesterol levels [10]. Anti-oxidant action is one of the pleiotropic effects of 
statins [11, 12]. We and other previously reported that statins enhanced the 
PON1 gene promoter activity in a human hepatocellular carcinoma cell line, 
HepG2 cells [13], or increased the serum PON1 concentrations and activities in 
patients with hypercholesterolemia [14].  
 We showed previously that PON1 gene promoter activity in HepG2 cells 
was modulated by an interaction between Sp1 and PKC [15]. Sp1 is an 
ubiquitous transcription factor and is well known to bind to GC-rich nucleotide 
sequences (GC boxes). Sp1 reportedly activates PON1 gene transcriptions [13, 
16]. PKC family is a serine/threonine kinase, and divides into three classes 
(which consist of at least 12 isoforms); conventional PKC (PKCα, βI, βII and γ), 
novel PKC (PKCδ, ε, η, θ and μ) and atypical PKC (PKCζ, and τ/λ). PKC play 
important roles in intracellular signal transduction mechanisms for hormones 
and growth factors, and individual isoforms have their distinct functional roles in 
the cells [17, 18]. Also, several investigators have reported interactions between 
  
Sp1 and PKC, especially PKCζ isoform, in the regulation of several gene 
expressions such as vascular endothelial growth factor gene, platelet-derived 
growth factor B-chain gene or insulin-like growth factor-II gene [19-21]. 
 In the present study, we investigated whether the mechanism of PON1 
gene promoter activation by pitavastatin was associated with PKC in cultured 
human hepatoma Huh7 cells in vitro. Here we demonstrate that pitavastatin 
increases PON1 gene promoter activity and PON1 protein expression and that 
these effects are regulated by PKC activation.
  
Materials and Methods 
Cell culture 
 Huh7 cells were cultured and maintained in Dulbecco's modified Eagle's 
medium (DMEM) (Sigma, St. Louis, MO) supplemented with 10% 
heat-inactivated fetal calf serum  (Life Technologies, Rockville, MD), 100 U/ml 
penicillin (Life Technologies) and 20 μg/ml streptomycin (Life Technologies) in 
90-mm plastic plates (Nunc, Roskilde, Denmark), and incubated at 37°C in 5% 
CO2. The cells were seeded into 90-mm plastic plates and routinely passaged 
every 3-4 days. These cells were seeded into 24-well plastic plates (Corning, 
Corning, NY) for luciferase assays and 6-well plastic plates (Nunc) for Western 
blotting. 
 
Reagents and Treatment 
 Pitavastatin was gifted from Kowa Company, Ltd (Tokyo, Japan). 
bisindolylmaleimide IX (Ro-31-8220), bisindolylmaleimide I (BIM), 
calphostin C and Gö6976 were all purchased from Calbiochem (La Jolla, 
  
CA). Myristoylated pseudosubstrate peptide inhibitor of PKCζ (MyrPKCζ) 
was purchased from Biomol (Plymouth, PA). All of the above reagents were 
dissolved in dimethylsulfoxide (DMSO) (Nakarai Tesque, Kyoto, Japan) 
adjusted with DMEM to a final concentration of 0.1%. The medium of 
control wells was adjusted to 0.1% DMSO. Before treatment with each 
reagent, the wells were washed twice with phosphate buffer saline, pH7.4 
and then the medium was changed to fresh DMEM without fetal calf serum. 
Each reagent treatment was started at 120 min after transfection, and 
cultured cells were harvested at 24h for luciferase assay, Western blotting 
or electrophoretic mobility shift assay (EMSA). Pitavastatin was added at 
120 min after pretreatment with each inhibitor. 
 
Plasmid constructs and transfection 
 We used plasmid constructs with PON1 gene 5’-flanking regions for 
luciferase assay, as reported previously [22]. pGL3 luciferase reporter vectors 
(Promega, Madison, WI) introduced DNA fragments of PON1 genes (-1230/-6) 
  
[pGL3-PON1 (-1230/-6)] were used in the present study. The number of DNA 
fragments is shown from the ATG start codon because of multi-transcription 
sites of the PON1 genes. We constructed an expression vector of PKCζ and 
mutated PKCζ (PKCζDN), which had mutated form of ATP binding site in kinase 
domain for mammalian cells, as reported previously [15].  
 Transient transfection into Huh7 cells was performed using a cationic lipid 
method employing Tfx-20 (Promega), as reported previously [13, 15]. PON1 
plasmid DNA was cotransfected with the pRL-TK vector (Promega), which 
expressed Renilla luciferase for an internal control. Cell extracts were prepared 
at 24h for the luciferase activity assay. Both firefly and Renilla luciferase 
activities in the cell lysates were measured using the Dual-Luciferase® Reporter 
Assay System (Promega). Promoter activities were expressed as firefly 
luciferase activity divided by Renilla luciferase activity. Six wells were used for 
each transfection condition. Each examination was repeated at least three times, 
and representative results are shown. 
 
  
Cell lysis and Western blotting 
 Huh7 cells were grown to confluence, and subsequently harvested and 
lysed as described previously [15]. The protein concentration was adjusted 
(Bio-Rad Protein Assay, Bio-Rad, Hercules, CA). Western blotting was 
performed as described previously [15]. First-antibodies for PON1 [23], 
α-tubulin (Sigma), PKCζ (Santa Cruz Biotechnology, Santa Cruz, CA), 
phospho-PKCα/βI/βII/δ/ε/η/θ (Cell Signaling, Beverly, MA) and phospho-PKCζ/λ 
(Cell Signaling) were used for blotting. Immunoreactive proteins were made 
visible using horseradish-peroxidase coupled secondary antibodies and ECL 
Plus Western Blotting Detection System (Amersham Pharmacia Biotech, 
Arlington Heights, IL). Each experiment was repeated at least three times, and 
representative results are shown. 
 
Preparation of nuclear extracts and EMSA 
 Huh7 cells were grown to confluence and harvested, and the nuclear 
fraction was isolated and extracted as described previously [13, 15]. EMSA was 
  
performed as described previously [13, 15]. The synthetic sense and antisense 
strands of oligonucleotides (-187/-159) were 
5’-GGTGGGGGCTGACCGCAAGCCGCGC-3’ and 
5’-GGCGCGGCTTGCGGTCAGCCCCCAC-3’, respectively. For a supershift 
study, Sp1-specific polyclonal antibody (PEP2) (Santa Cruz Biotechnology, 
Santa Cruz, CA) was used. The dried gel was analyzed by a computerized 
system for radioluminography (BAS2500, Fuji Photo Film, Kanagawa, Japan) 
and for analyzing software (MacBAS version 2.3, Fuji Photo Film). The 
intensities of bands were compared by using the software. Each experiment 
was repeated at least three times, and representative results are shown. 
 
Statistical analysis 
 Statistical differences among three groups or more were determined by 
analysis of variance (ANOVA).  Comparisons for two groups were performed 
using the Fisher’s test.  P values less than 0.05 were considered statistically 
significant. 
  
Results 
Effects of PKC inhibitors on pitavastatin-enhanced PON1 promoter 
activity and PON1 protein expression 
 Pitavastatin 50µM significantly enhanced the promoter activity of PON1 
gene in Huh7 cells (Fig 1). This result was consistent with our previous report in 
HepG2 cells [13]. Then we examined whether PKC pathway was involved in 
pitavastatin-induced PON1 promoter activation. Both 1µM Ro-31-8220 (a 
pan-PKC inhibitor) and 1µM BIM (a pan-PKC inhibitor) abolished 
pitavastatin-induced promoter activation (Fig 1A).  
 Next, we studied the effects of these PKC inhibitors on the PON1 protein 
expression in Huh7 cells. The PON1 protein expression in Huh7 cells was 
significantly increased by 10μM pitavastatin (p<0.01), and both 1µM 
Ro-31-8220 and 1µM BIM attenuated this effect after 24h (Fig 1B).  
 
Effect of PKC inhibitor on Sp1 binding to PON1 DNA 
 Since pitavastatin enhanced PON1 promoter activity through transcription 
  
factor Sp1 [13, 15, 16], and PKC inhibitors declined pitavastatin-enhanced 
PON1 promoter activity and protein expression, we investigated the effect of 
PKC inhibitor on the binding of Sp1 to DNA fragments of the PON1 gene 
promoter (-187/-159). Treatment with 50µM pitavastatin increased the band 
intensity of Sp1-DNA complex (p <0.05), however, pretreatment with 1µM 
Ro-31-8220 abolished the pitavastatin-increased band intensity (Fig. 2A, B). 
Sp1-DNA complex bands (indicated by an asterisk) were also attenuated by 
competitor (unlabeled DNA fragments) and supershifted by the anti-Sp1 
antibodies (double asterisks) (Fig 2A). 
 
Effect of pitavastatin on the activation of PKC isoforms 
 We carried out immunoblotting in order to identify which PKC isoforms 
were possibly participated in the regulation of PON1 gene transcription and 
PON1 protein expression in Huh7 cells. Pitavastatin 50µM phosphorylated 
PKCζ/λ, meanwhile PKCα, βI, βII, δ, ε, η and θ were not phosphorylated by 
pitavastatin stimulation (Fig 3A and 3B). We calculated relative 
  
phospho-PKCζ/λ band intensities and demonstrated that pitavastatin 10μM 
significantly increased the band intensity after 60 min incubation (p<0.05) 
(Figure 3C). 
 MyrPKCζ, a specific inhibitor for PKCζ but not PKCλ, 30µM abolished the 
pitavastatin-induced promoter activation (Fig 4A). However 200nM calphostin C 
and 1µM Gö6976 that were inhibitors of PKC except for atypical PKCζ, did not 
influence on pitavastatin-induced PON1 promoter activation (Fig 4B and 4C).  
 
Effect of dominant negative form of PKCζ expression vector on 
pitavastatin-induced PON1 promoter activation 
 Finally, we studied the effect of co-transfection with dominant negative 
form of PKCζ expression vector (PKCζDN) on pitavastatin-induced PON1 
promoter activation. An overexpression of wild type PKCζ did not influenced on 
pitavastatin-induced PON1 promoter activation in Huh7 cells (Fig 5A). However 
an overexpression of PKCζDN obviously decreased pitavastatin-induced PON1 
promoter activation (Fig 5B).  
  
Discussion 
 In the present study, pitavastatin enhanced PON1 gene promoter activity 
and PON1 protein expression through the activation of PKC in Huh7 cells. To 
the best of our knowledge, our result of PKC activation by pitavastatin is the first 
report. We also revealed that pitavastatin increased PON1 promoter activity 
through the activation of PKCζ isoform but not other PKC isoforms.  
 Protein kinase is an enzyme family that phosphorylates various protein 
molecules and as intracellular signal transduction and metabolic modulating 
factor. Recently, statins were reported to have various effects through PKA, 
PKB, PKC or PKG [24-27]. We previously reported that PON1 gene promoter 
activity in HepG2 cells was regulated by PKC activation [15], and was enhanced 
by pitavastatin stimulation [13]. However it remained unclear whether 
pitavastatin-induced PON1 promoter activation was associated with PKC. To 
investigate the signal transduction pathway(s) involved in regulating PON1 gene 
transactivation in response to pitavastatin stimulation, we firstly examined the 
effects of chemical inhibitors of signaling intermediates on PON1 gene promoter 
  
activity. We defined in this study that pitavastatin increased-PON1 gene 
promoter activity was associated with PKC activation (Fig 1). Moreover we 
demonstrated that PON1 protein expression in Huh7 cells was also increased 
by pitavastatin through PKC activation (Fig 1B).  
 Protein phosphorylation of transcription factor is one of the major 
mechanisms to regulate the binding activity of the factor to DNA either positively 
or negatively. It has been reported that Sp1 phosphorylation increases the 
capacity of Sp1 to bind DNA, and PKC, especially atypical PKCζ isoform, plays 
a crucial role in Sp1 phosphorylation [19-21]. Sp1 was previous reported to 
activate PON1 gene transcriptions [13, 15, 16]. In the result, our EMSA showed 
that the binding intensity of Sp1 to DNA fragments of PON1 promoter was 
increased by treatment with pitavastatin and that Ro-31-8220 attenuated 
pitavastatin-increased band intensity of the Sp1-DNA complex (Fig 2). These 
results suggest that pitavastatin increases Sp1-DNA binding through activation 
of PKC. 
 
  
 We demonstrated that pitavastatin activated PKCζ/λ isoforms, but not 
PKCα, βI, βII, δ, ε, η and θ isoforms. We previously reported that PON1 gene 
promoter activity in HepG2 cells was regulated by atypical PKCζ as well as 
conventional PKCα [15], however we can hardly say with any finality that 
pitavastatin increased PON1 promoter activity through atypical PKCζ. 
Consequentially, we next set out to dissect the role of PKCζ in 
pitavastatin-induced PON1 promoter activation. MyrPKCζ, a specific PKCζ 
inhibitor abolished the pitavastatin-induced PON1 promoter activation, but 
calphostin C and Gö6976, inhibitors of PKCs except for PKCζ inhibition did not 
influence on the promoter activation (Fig 4). Additionally, PKCζDN abolished the 
pitavastatin-enhanced promoter activity (Fig 5). These observations suggest 
that pitavastatin-induced transcription is regulated not by classical or novel PKC 
but by atypical PKCζ. 
 Some previous reports showed that statins influenced on the activity of 
various PKC isoforms. Atorvastatin inhibited PKC inhibitors-induced apoptosis 
of adult rat cardiac myocytes through PKCδ pathway [26]. On the other hand, 
  
some studies in different cell systems showed that stains inhibited the activation 
of PKC. Ceolotto C et al. reported that pravastatin inhibited radical oxygen 
species production by inhibiting PKCδ in human fibroblast [28]. Maeda K et al. 
reported that pitavastatin suppressed the expression of PKCα, βI in 
polymorphonuclear leukocytes from hyperlipidemic guinea pig [29]. Yasunari K 
et al. also reported that statins have direct antimigratory effects via suppression 
of PKCα in human vascular smooth muscle cell [30]. The differences of those 
cell types and stimulation conditions may determine the outcome of PKC 
activation and may be responsible for incompatible function on the stimulating 
cells. Zhang Y et al. reported that PKCζ was responsible for the marked Sp1 
phosphorylation induced by trichostatin A in JAR cells [31]. Pal S et al. revealed 
that PKCζ promoted the Sp1-mediated transcription of vascular permeability 
factor/vascular endothelial growth factor in human HT1080 and 786-0 cells [32]. 
Our observations were not inconsistent with these previous reports, 
consequently, we suppose that pitavastatin-activated PKCζ may be increased 
Sp1-PON1 DNA binding. 
  
 Many pleiotropic effects of statins have been reported to depend on 
stains-induced depletion of isoprenoids in the mevalonic acid cascade. We 
reported that depletion of farnesyl pyrophosphate by pitavastatin was 
associated with pitavastatin-increased PON1 promoter activity in HepG2 cell 
[13]; moreover, it was recently reported that pitavastatin also induced PON1 
expression through activation of the p44/42 mitogen-activated protein kinase 
signaling cascade in Huh7 cells [33]. To our best knowledge, it was only one 
report to refer the association with statins-influenced PKC activity and 
isoprenoids, which fluvastatin-decreased PKC activity was reversed by 
isoprenoids [30]. However, we determined that pitavastatin-activated PKCζ was 
not reversed by supplement of isoprenoids, such mevalonic acid, farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate in this study (data not 
shown). Furthermore, we could also not clarify the relationship between the 
p44/42 MAP kinase signaling cascade and PKCζ in this study. That is to say, it 
may yet not be reasonable to presume that pitavastatin-activated PKCζ is 
associated with depletion of isoprenoids in the mevalonic acid cascade and 
  
more detailed studies are required to establish the relationship between 
pitavastatin-activated PKCζ and the p44/42 MAP kinase signaling cascade. On 
the other hand, in contrast to our results, some statins, such as pravastatin, 
simvastatin and fluvastatin, have been reported previously, to decrease PON-1 
expression [34]. We speculate that the differences in the type of statins and 
stimulation conditions may determine the outcome of the effect of statins on 
PON1 expression, and may explain their inconsistent actions on the Huh7 cells. 
 In conclusion, pitavastatin may activate atypical PKCζ followed by increase 
in the binding of Sp1 to the PON1 gene promoter region, and pitavastatin 
enhances PON1 gene transactivation and PON1 protein expression.  
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Figure Legends 
Figure 1. Role of PKC in pitavastatin-enhanced PON1 promoter activity and 
PON1 protein expression in Huh7 cells. 
(A) pGL3-PON1 (-1230/-6) plasmid was transfected into Huh7 cells and treated 
with PKC inhibitors; 1µM Ro-31-8220 or 1µM BIM, and with 50µM pitavastatin. 
Each column represents mean ± S.E.M. of data from 6 wells. (B) Cultured cells 
treated with 1µM Ro-31-8220 or 1µM BIM were stimulated with 10µM 
pitavastatin. Aliquots of whole-cell lysate were obtained, and immunoblotting 
was performed with antibody to PON1 or α-tubulin. Internal control was 
evaluated by α-tubulin. Relative PON1 protein expressions (PON1/α-tubulin) 
were calculated. Each column represents mean ± S.E.M. of data from 3 wells. 
 
Figure 2. Role of PKC in the binding of Sp1 to the PON1 gene DNA fragment 
(-187/-159) in Huh7 cells.  
(A) Lane 1, no nuclear extracts; lane 2, DNA fragments and nuclear extracts 
from Huh7 cells; lane 3, DNA fragments and nuclear extracts treated with 50µM 
  
pitavastatin; lane 4, DNA fragments and nuclear extracts treated with 1µM 
Ro-31-8220; lane 5, DNA fragments and nuclear extracts treated with both 
pitavastatin and Ro-31-8220; lane 6, DNA fragments, nuclear extracts, and 
anti-Sp1 antibody; lane 7, DNA fragments, nuclear extracts, and competitor 
(unlabeled-DNA fragments). ∗, Sp1-DNA complex band; ∗∗, Sp1-DNA- Sp1 
antibody complex band. (B) Calculated relative intensities of the Sp1-DNA 
complex band. Each column represents mean ± S.E.M. of data from 3 wells. 
 
Figure 3. Effect of pitavastatin on the activation of PKC isoforms in Huh7 cells.  
Cultured cells were stimulated with 50µM pitavastatin. Aliquots of whole-cell 
lysate were obtained, and immunoblotting was performed with specific antibody 
for phospho-PKCζ/λ (A) or phospho-PKCα/βI/βII/δ/ε/η/θ (B). Antibodies for both 
α-tubulin and PKCζ were used for internal control. Calculated relative intensities 
of the phospho-PKCζ/λ band (phospho-PKCζ/λ / α-Tubulin) after 1h incubation. 
Each column represents mean ± S.E.M. of data from 3 wells (C). 
 
  
Figure 4. Role of PKCζ in pitavastatin-enhanced PON1 promoter activity in 
Huh7 cells. 
pGL3-PON1 (-1230/-6) plasmid was transfected into Huh7 cells and treated with 
30µM MyrPKCζ (A), 200nM calphostin C (B), 1µM Gö6976 (C), and with 50µM 
pitavastatin. Each column represents mean ± S.E.M. of data from 6 wells. 
 
Figure 5. Effect of dominant negative form of PKCζ on pitavastatin-induced 
PON1 promoter activation in Huh7 cells.   
pGL3-PON1 (-1230/-6) plasmid was transfected into Huh7 cells and the wild 
type PKCζ expression plasmid (PKCζ), dominant negative type PKCζ 
expression plasmid (PKCζDN) or an empty vector (PCLneo) was 
simultaneously cotransfected. The luciferase activity was measured 24hr after 
50µM pitavastatin stimulation. Each column represents mean ± S.E.M. of data 
from 6 wells. 
 





